FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Ragosa Mark						2. Issuer Name and Ticker or Trading Symbol Kiniksa Pharmaceuticals, Ltd. [KNSA]									tionship of Reporting all applicable) Director Officer (give title		g Person(s) to Issu 10% Ow Other (s		ner
	IIKSA PHA	irst) ARMACEUTICA USE 2 CHURCH			09	3. Date of Earliest Transaction (Month/Day/Year) 09/01/2022									below) CHIEF	FINAN		below)	R
(Street) HAMILT		itate)	HM 11 (Zip)		-	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Line) X Form filed by One Reporting Person Form filed by More than One R										rting Persor	1		
1. Title of	Security (Ins	vativ sactio	ative Securities Acquired, Disposed of, or Benefi					d (A) or	or 5. Amount of					7. Nature of					
Date (Month/D					/Day/Y	ay/Year) Execution if any (Month/Day		,	Transaction Code (Instr. 8)					Ben Owr		neficially vned Following		Indirect str. 4)	Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Class A Common Share 09/02				2/202	2/2022		M		1,861	A	(1))	8,218		D				
Class A Common Share 09/0			09/0	2/202	2/2022			F		547	D	\$11.	.44	7,671			D		
			Table II -								osed of, onvertib			y O	wned			,	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	se (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, T	ransaction code (Instr.		Derivative		6. Date Exerci Expiration Dat (Month/Day/Ye		e of Securi ear) Underlyii		rities ring ve Security		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti	G F	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				C	Code	v	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title	Amour or Number of Shares	ər		(Instr. 4)	on(s)		
Share Option	\$11.97	09/01/2022			Α		64,660		(2)		08/31/2032 Class A Common Share 64		64,66	50	\$0	64,660		D	
Restricted Share Unit	(1)	09/01/2022			A		10,777		(3)		(3)	Class A Common Share	10,77	77	\$0	0 10,777		D	
Restricted Share Unit	(1)	09/02/2022			M			1,861	(4)		(4)	Class A Common Share	1,86	1	\$0	5,583	3	D	

Explanation of Responses:

- 1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
- 2. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022.
- 3. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
- 4. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.

/s/ Madelyn Zeylikman, Attorney-in-Fact 09/06/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.